| P2093 | author name string | Gajanan S Inamdar | |
| | Gavin P Robertson | |
| | SubbaRao V Madhunapantula | |
| P2860 | cites work | Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF | Q24298749 |
| | PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells | Q24606438 |
| | CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations | Q24618486 |
| | Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity | Q24652600 |
| | Rewired ERK-JNK signaling pathways in melanoma | Q24683737 |
| | Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors | Q27349020 |
| | RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth | Q27659493 |
| | MEK1 mutations confer resistance to MEK and B-RAF inhibition | Q27777362 |
| | Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers | Q27851426 |
| | Mutations of the BRAF gene in human cancer | Q27860760 |
| | A dimerization-dependent mechanism drives RAF catalytic activation | Q27865239 |
| | Negative regulation of the serine/threonine kinase B-Raf by Akt | Q28139252 |
| | Determinants of BRAF mutations in primary melanomas | Q28191720 |
| | Novel cross talk between MEK and S6K2 in FGF-2 induced proliferation of SCLC cells | Q28213233 |
| | Macrophage inhibitory cytokine-1 is overexpressed in malignant melanoma and is associated with tumorigenicity | Q39946272 |
| | Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma | Q39971699 |
| | Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development | Q39976180 |
| | Simultaneous knockdown of BRAF and expression of INK4A in melanoma cells leads to potent growth inhibition and apoptosis | Q39993343 |
| | Inducible BRAF suppression models for melanoma tumorigenesis | Q39997379 |
| | Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma. | Q40005196 |
| | Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells | Q40005203 |
| | Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. | Q40014237 |
| | Inhibition of MEK sensitizes human melanoma cells to endoplasmic reticulum stress-induced apoptosis | Q40066391 |
| | Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. | Q40079043 |
| | AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl | Q40093939 |
| | ERK1/2 is highly phosphorylated in melanoma metastases and protects melanoma cells from cisplatin-mediated apoptosis | Q40131845 |
| | Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. | Q40153829 |
| | In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling | Q40224091 |
| | Functional analysis of the regulatory requirements of B-Raf and the B-Raf(V600E) oncoprotein | Q40279488 |
| | Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors | Q40444060 |
| | V599EB-RAF is an oncogene in melanocytes | Q40520428 |
| | B-RAF is a therapeutic target in melanoma | Q40543086 |
| | The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis | Q40820545 |
| | Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. | Q40887108 |
| | Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. | Q41859138 |
| | Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells | Q42803458 |
| | Preclinical pharmacology of BMS-275183, an orally active taxane | Q43670896 |
| | Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor | Q43770326 |
| | Farnesyl thiosalicylic acid chemosensitizes human melanoma in vivo | Q44282926 |
| | Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma | Q45183209 |
| | BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. | Q45252786 |
| | A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel | Q46448115 |
| | Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies | Q46595207 |
| | Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group | Q46619788 |
| | The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel | Q46825496 |
| | Conformational restriction of flexible ligands guided by the transferred noe experiment: potent macrocyclic inhibitors of farnesyltransferase | Q49308943 |
| | Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma | Q53640355 |
| | U0126, a mitogen-activated protein kinase kinase inhibitor, inhibits the invasion of human A375 melanoma cells | Q53754222 |
| | BRAF inhibitors: research accelerates in wake of positive findings. | Q54693415 |
| | Simultaneous inhibition of MEK and CDK4 leads to potent apoptosis in human melanoma cells. | Q54705317 |
| | BRAF mutations in metastatic melanoma: a possible association with clinical outcome. | Q54756359 |
| | Recent Trends in Cutaneous Melanoma Incidence Among Whites in the United States | Q57308234 |
| | Metastasizing Melanoma Formation Caused by Expression of Activated N-RasQ61Kon an INK4a-Deficient Background | Q58379806 |
| | Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation | Q73013877 |
| | Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model | Q79436243 |
| | Nanostructure-mediated drug delivery | Q79755442 |
| | Raf kinase inhibitors in oncology | Q81307807 |
| | Oncogenic BRAF is required for tumor growth and maintenance in melanoma models | Q82310241 |
| | [A trip through the signaling pathways of melanoma] | Q83179515 |
| | Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases | Q37421620 |
| | Melanoma: molecular pathogenesis and emerging target therapies (Review). | Q37474412 |
| | BRAF signaling and targeted therapies in melanoma | Q37493375 |
| | The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma | Q37506648 |
| | Melanoma arising in African-, Asian-, Latino- and Native-American populations | Q37553340 |
| | Emerging Raf inhibitors. | Q37588717 |
| | SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant | Q38337665 |
| | Preclinical in vivo evaluation of efficacy, pharmacokinetics, and pharmacodynamics of a novel MEK1/2 kinase inhibitor RO5068760 in multiple tumor models | Q39755197 |
| | C-Raf inhibits MAPK activation and transformation by B-Raf(V600E). | Q39773963 |
| | ERK-regulated differential expression of the Mitf 6a/b splicing isoforms in melanoma | Q39778248 |
| | Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. | Q39782693 |
| | Braf(V600E) cooperates with Pten loss to induce metastatic melanoma | Q39873596 |
| | Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. | Q39899988 |
| | Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF | Q28251989 |
| | Guilty as charged: B-RAF is a human oncogene | Q28288202 |
| | Cancer statistics, 2009 | Q29547625 |
| | BRAF mutation predicts sensitivity to MEK inhibition | Q29614281 |
| | Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles | Q29615957 |
| | RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF | Q29616828 |
| | BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis | Q29617585 |
| | Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer | Q29618155 |
| | BRAFE600-associated senescence-like cell cycle arrest of human naevi | Q29619550 |
| | The RAF proteins take centre stage | Q29620153 |
| | Essential role for oncogenic Ras in tumour maintenance | Q30150290 |
| | Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. | Q31982994 |
| | Cisplatin encapsulated in phosphatidylethanolamine liposomes enhances the in vitro cytotoxicity and in vivo intratumor drug accumulation against melanomas | Q33271246 |
| | Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma | Q33384029 |
| | Targeting Akt3 signaling in malignant melanoma using isoselenocyanates | Q33408109 |
| | Oncogenic BRAFV600E induces expression of neuronal differentiation marker MAP2 in melanoma cells by promoter demethylation and down-regulation of transcription repressor HES1. | Q33581231 |
| | Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling | Q33613978 |
| | The role of interleukin-2 in the management of stage IV melanoma: the EORTC melanoma cooperative group program | Q33844228 |
| | The emerging role of cytokines in the treatment of advanced melanoma. For the EORTC Melanoma Cooperative Group | Q33855581 |
| | BRAF V600E mutation and the tumour suppressor IGFBP7 in atypical genital naevi | Q34063848 |
| | Epidemiology of skin cancer | Q34143044 |
| | Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials | Q34186952 |
| | Blocking oncogenic Ras signaling for cancer therapy | Q34311585 |
| | Farnesyltransferase inhibitors: mechanism and applications | Q34481874 |
| | Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases | Q34531564 |
| | Raf proteins and cancer: B-Raf is identified as a mutational target | Q34648534 |
| | Oncogenic Braf induces melanocyte senescence and melanoma in mice | Q34974162 |
| | Farnesyl transferase inhibitors in the treatment of breast cancer | Q35073354 |
| | Melanoma chemoprevention: a role for statins or fibrates? | Q35131257 |
| | Cooperative effects of INK4a and ras in melanoma susceptibility in vivo | Q35195311 |
| | BRAF as a potential therapeutic target in melanoma and other malignancies | Q35212513 |
| | Pharmacological inhibitors of the ERK signaling pathway: application as anticancer drugs | Q35573664 |
| | Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. | Q35588829 |
| | Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation. | Q35779541 |
| | Roles of NF-kappaB and bcl-2 in two differential modes of cell death of mouse cortical collecting duct cells | Q36017643 |
| | The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma | Q36170391 |
| | Chemotherapy for metastatic melanoma | Q36352095 |
| | Engineered nanoparticles as precise drug delivery systems. | Q36379031 |
| | Chemotherapy and targeted therapy combinations in advanced melanoma | Q36445966 |
| | Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma | Q36445971 |
| | Molecular targets in melanoma from angiogenesis to apoptosis. | Q36445976 |
| | Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104) | Q36526919 |
| | Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway | Q36557277 |
| | Therapeutic targets in melanoma: map kinase pathway | Q36562233 |
| | Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels. | Q36609858 |
| | Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. | Q36610990 |
| | Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis | Q36612290 |
| | Sorafenib: delivering a targeted drug to the right targets | Q36817095 |
| | B-Raf kinase inhibitors for cancer treatment | Q36875829 |
| | Recent advances of MEK inhibitors and their clinical progress | Q36907524 |
| | BRAF(E600) in benign and malignant human tumours | Q36921234 |
| | p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors | Q36944185 |
| | Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials | Q37008436 |
| | Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival | Q37015135 |
| | The genome and epigenome of malignant melanoma | Q37016230 |
| | Recent discoveries in the genetics of melanoma and their therapeutic implications | Q37024839 |
| | Understanding signaling cascades in melanoma | Q37034487 |
| | Is B-Raf a good therapeutic target for melanoma and other malignancies? | Q37048982 |
| | Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas | Q37118264 |
| | Emerging therapies for melanoma | Q37134426 |
| | Integrating BRAF/MEK inhibitors into combination therapy for melanoma. | Q37135238 |
| | Modulation of the Akt/Ras/Raf/MEK/ERK pathway by A₃ adenosine receptor | Q37135531 |
| | Therapeutic strategies for targeting BRAF in human cancer | Q37161265 |
| | Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy | Q37194874 |
| | The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes | Q37197419 |
| | Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations | Q37269341 |
| | Targeting mutant (V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation. | Q37299513 |
| | Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway. | Q37370630 |
| | Targeting the RAF-MEK-ERK pathway in cancer therapy | Q37393116 |
| | Use of liposomes as drug delivery vehicles for treatment of melanoma. | Q37406217 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 624-637 | |
| P577 | publication date | 2010-05-09 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Biochemical Pharmacology | Q864229 |
| P1476 | title | Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail | |
| P478 | volume | 80 | |